What Is Zepbound Used For? Approved Uses and Mechanism

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This guide lives in the PlexusDx Education Hub, where we unpack GLP-1 science, weight-management protocols, and the genetic factors behind metabolic decisions. Open the Education Hub

What Zepbound is

Zepbound is Eli Lilly's brand of tirzepatide, a GIP/GLP-1 dual agonist. Within the tirzepatide brands, the FDA approvals split by product and indication: Mounjaro for type 2 diabetes, and Zepbound for chronic weight management and, since 2024, obstructive sleep apnea in adults with obesity. The dual mechanism is the distinguishing feature of the molecule. This overview covers its uses, mechanism, side effects, and cost as of April 2026. Open the Education Hub.

What Zepbound is approved for

Zepbound carries two FDA-approved indications: chronic weight management and obstructive sleep apnea in adults with obesity, the latter added in 2024. That sleep apnea approval is a meaningful distinction, since it is specific to Zepbound within the class. As always, prescribing follows the brand's FDA-approved indication, and the same molecule under a different brand is not automatically interchangeable for insurance or coverage purposes.

How the dual mechanism works

GLP-1 receptor agonists engage the GLP-1 receptor in the pancreas, hypothalamus, and gastrointestinal tract, slowing gastric emptying, blunting post-meal glucose excursions, reducing appetite, and increasing satiety signaling. Tirzepatide, as a GIP/GLP-1 dual agonist, additionally engages the GIP receptor, adding a second incretin mechanism. Weekly dosing delivers sustained receptor engagement across both pathways, which is what sets this molecule apart from GLP-1-only compounds. That dual design is also why Zepbound is discussed separately from single-receptor medicines when providers weigh mechanism against a patient's clinical goals.

Where it sits in the broader class

For context, FDA-approved indications across the class include type 2 diabetes for most compounds, chronic weight management for Wegovy, Saxenda, and Zepbound, cardiovascular risk reduction in type 2 diabetes for several products, and obstructive sleep apnea in adults with obesity for Zepbound. Understanding those distinctions clarifies why coverage and eligibility differ from one brand to the next.

Common side effects

Gastrointestinal symptoms, including nausea, vomiting, diarrhea, and constipation, are the most commonly reported and are usually most pronounced during dose titration. All FDA-approved GLP-1 compounds carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies. Rare serious events include pancreatitis, gallbladder disease, and acute kidney injury in the context of dehydration.

Cost and access

Manufacturer list prices for FDA-approved branded products typically range from $800 to $1,600 per month at U.S. list as of April 2026. Out-of-pocket cost depends on insurance coverage, the FDA indication on the prescription, manufacturer savings card eligibility, and whether a compounded alternative is available through a licensed 503A pharmacy pathway.

Why the sleep apnea approval stands out

Zepbound's 2024 approval for obstructive sleep apnea in adults with obesity is notable because it extended a weight-management medicine into a distinct clinical condition. It reflects how the dual GIP/GLP-1 mechanism is being studied and applied beyond glucose and weight alone. For patients, the practical takeaway is that indications within the tirzepatide brands are specific: Mounjaro for type 2 diabetes, Zepbound for chronic weight management and, additionally, obstructive sleep apnea in adults with obesity. Because prescribing follows the brand's approved indication, the brand chosen and the condition being treated are tightly linked, which in turn shapes coverage and eligibility. If you are exploring Zepbound for any of these reasons, the useful conversation with a provider centers on which indication applies to you and whether you meet the criteria on the product label.

The genetic context underneath

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, available as injection and oral options such as Tirzepatide Injection. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including variants in FTO, GLP1R, MC4R, and TCF7L2 that shape baseline appetite and energy balance. It does not predict response to Zepbound or any medication; it provides pathway-level context.

Frequently Asked Questions

What conditions is Zepbound approved to treat?

Zepbound is FDA-approved for chronic weight management and, since 2024, obstructive sleep apnea in adults with obesity. Both are specific to the Zepbound brand of tirzepatide. Prescribing follows the brand's approved indication, so it is not automatically interchangeable with Mounjaro, which is approved for type 2 diabetes.

How is Zepbound different from GLP-1-only drugs?

Zepbound's active ingredient, tirzepatide, is a GIP/GLP-1 dual agonist. It engages the GLP-1 receptor and additionally the GIP receptor, adding a second incretin mechanism that GLP-1-only medicines do not have. Weekly dosing sustains engagement across both pathways, which is the molecule's defining characteristic within the class.

What side effects are most common?

Gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation are most commonly reported, usually strongest during dose titration. The class carries a boxed warning for thyroid C-cell tumor risk seen in rodent studies, and rare serious events include pancreatitis, gallbladder disease, and acute kidney injury in the setting of dehydration.

Can genetics predict my Zepbound results?

No. The Precision Peptide Genetic Test does not predict response to Zepbound or any specific medication. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that shape baseline energy-balance biology, offering upstream context that applies across every GLP-1 pathway compound in the class.

Keep reading across the PlexusDx Education Hub for more evidence-based GLP-1 and metabolic health explainers. Return to the Education Hub

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.